- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.02. | With declining sales of legacy meds, BMS leans on new growth drivers to weather the storm | ||
| 05.02. | Astellas tops expectations as Vyloy sales surge outshines trial setback | ||
| 05.02. | A cut above: Veradermics locks in $256M IPO and shares spike | ||
| 05.02. | Merz steps into the ring with Muhammad Ali-inspired Inbrija campaign | ||
| 04.02. | FDA's rare pediatric disease voucher program revived by 2026 government funding bill | ||
| 04.02. | Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026 | ||
| 04.02. | AbbVie, hitting record sales on Skyrizi gains, holds its own in growing IBD arena despite J&J competition | ||
| 04.02. | Novartis CEO projects 2026 growth despite 'largest patent expiry' in company history | ||
| 04.02. | BMS celebrates US soccer legend's shutout against cancer in Breyanzi collab | ||
| 04.02. | OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts | ||
| 04.02. | As CEO, Luke Miels wants GSK to be more 'product-centric' | ||
| 04.02. | Amgen resists FDA request to pull rare disease drug Tavneos from the market | ||
| 03.02. | India will invest $1.1B to boost development of biologics, biosimilars | ||
| 03.02. | Novo shares plummet on sales, profit warning for '26 as 2 top execs head for the doors | ||
| 03.02. | Charles River to close cell therapy CDMO site, lay off 20 staffers | ||
| 03.02. | Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade | ||
| 03.02. | FDA signals tailored approach to 'carefully shepherd' CAR-T therapy for autoimmune diseases | ||
| 03.02. | BMS, J&J factor in HCP education on clot-busting mechanism before milvexian data drop | ||
| 03.02. | FDA rejects AstraZeneca's subQ Saphnelo, but company expects quick turnaround for new approval decision | ||
| 03.02. | Sanofi sanctioned by PMCPA over CEO's 'bold claims' about Pfizer RSV vaccine | ||
| 02.02. | AbbVie has 'Love in Mind' with new migraine educational campaign | ||
| 02.02. | Thermo Fisher trims Massachusetts headcount with Franklin site closure | ||
| 02.02. | With FDA rejections, Aquestive's shares go up, while Pharming's go down | ||
| 02.02. | FDA emphasizes drug ingredients, production pledges as it debuts PreCheck manufacturing program | ||
| 02.02. | Regulatory tracker: FDA sets decision date for Summit's PD-1xVEGF bid |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.